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OBJECTIVES The present study examined whether nitric oxide (NO) produced by inducible nitric oxide
synthase (iNOS) can directly inhibit aerobic energy metabolism and impair cell function in
interleukin (IL)-1b–stimulated cardiac myocytes.
BACKGROUND Recent reports have indicated that excessive production of NO induced by cytokines can
disrupt cellular energy balance through the inhibition of mitochondrial respiration in a variety
of cells. However, it is still largely uncertain whether the NO-induced energy depletion affects
myocardial contractility.
METHODS Primary cultures of rat neonatal cardiac myocytes were prepared, and NO2
2/NO3
2 (NOx) in
the culture media was measured using Griess reagent.
RESULTS Treatment with IL-1b (10 ng/ml) increased myocyte production of NOx in a time-
dependent manner. The myocytes showed a concomitant significant increase in glucose
consumption, a marked increase in lactate production, and a significant decrease in cellular
ATP (adenosine 59-triphosphate). These metabolic changes were blocked by co-incubation
with NG-monomethyl-L-arginine (L-NMMA), an inhibitor of NO synthesis. Sodium
nitroprusside (SNP), a NO donor, induced similar metabolic changes in a dose-dependent
manner, but 8-bromo-cyclic guanosine 39,59-monophosphate (8-bromo-cGMP), a cGMP
donor, had no effect on these parameters. The activities of the mitochondrial iron-sulfur
enzymes, NADH-CoQ reductase and succinate-CoQ reductase, but not oligomycin-sensitive
ATPase, were significantly inhibited in the IL-1b or SNP-treated myocytes. Both IL-1b and
SNP significantly elevated maximum diastolic potential, reduced peak calcium current (ICa),
and lowered contractility in the myocytes. KT5823, an inhibitor of cGMP-dependent protein
kinase, did not block the electrophysiological and contractility effects.
CONCLUSIONS These data suggest that IL-1b–induced NO production in cardiac myocytes lowers energy
production and myocardial contractility through a direct attack on the mitochondria, rather
than through cGMP-mediated pathways. (J Am Coll Cardiol 2000;35:1338–46) © 2000 by
the American College of Cardiology
Endogenously or exogenously produced nitric oxide (NO)
can cause negative inotropic effects in the cardiovascular
system (1–5). Consequently, a great deal of attention is
being focused currently on conditions that expose the heart
to elevated concentrations of NO. In examining the causes
of inflammation-induced myocardial injury, it has been
observed recently that the proinflammatory cytokines inter-
feron (IFN)-g, interleukin (IL)-1b, and tumor necrosis factor
(TNF)-a can increase NO synthesis by elevating the expres-
sion of inducible nitric oxide synthase (iNOS) (6), causing a
sustained depression in myocardial contractility (3,4,7), as well
as protracted hypotension during septic shock (8). However,
despite this recent elucidation of the conditions that promote
NO production in the inflamed heart, mechanisms of the
NO-induced injurious effects remain poorly understood.
Two potential mechanisms of NO damage are currently
favored. The first invokes an indirect mode of injury in
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which the NO-induced activation of soluble guanylate
cyclase causes the increased production of cGMP, which
then decreases myocardial contractility by decreasing cyto-
plasmic Ca21 concentration (1–4). The second and more
direct mechanism proposes that NO may inhibit the aerobic
energy–producing processes in the heart by directly altering
mitochondrial activity. Recent reports have shown that
iNOS-produced NO can cause inhibition of mitochondrial
respiration in a variety of cells, resulting in disturbances in
energy balance and cytotoxicity (9,10). Significantly, a
similar ability of cytokine-stimulated NO production to
inhibit mitochondrial activity has been documented recently
in cardiac myocytes as well. These studies (11,12) suggested
that iNOS-produced NO can diminish mitochondrial ac-
tivity, but they left unanswered the question of whether the
NO-induced energy depletion affects myocardial contractil-
ity.
The purpose of the present study was therefore to
elucidate the relationship between NO-induced energy
depletion and cell dysfunction and to determine which of
the two potential mechanisms for the NO-associated injury
occurs in IL-1b–treated cardiac myocytes. Using a previ-
ously established model of IL-1b–mediated iNOS induc-
tion in cardiac myocytes (13), we examined the ability of
NO to disrupt the glycolytic and energy-producing path-
ways by monitoring not only glucose and lactate content in
the culture media, but also lactate and ATP (adenosine
59-triphosphate) content in the myocytes themselves. To
examine the possible involvement of indirect injury by
cGMP, we treated myocytes with 8-bromo-cyclic guanosine
39,59-monophosphate (8-bromo-cGMP), a cGMP ana-
logue. To test for direct inhibition of mitochondrial activity,
we assayed the enzymatic activity of the NO-susceptible
mitochondrial iron-sulfur enzymes, NADH-coenzyme Q
(CoQ) reductase (complex I), succinate-CoQ reductase
(complex II), and oligomycin-sensitive ATPase (complex
V). Furthermore, we measured membrane potential, cal-
cium current, and myocyte contractility to assess myocyte
function.
METHODS
Materials. Recombinant IL-1b (lymphocyte-activating
factor, 2 3 107 U/mg protein) was a generous gift from
Otsuka Pharmaceutical Co. The 8-bromo-cyclic guanosine
39,59-monophosphate (8-bromo-cGMP), gentamycin, and
collagenase were obtained from Sigma Chemical, NG-
monomethyl-L-arginine (L-NMMA) from Calbiochem,
and other chemicals from Nacalai Tesque.
Culture of neonatal rat cardiac myocytes. Primary cul-
tures of rat neonatal cardiac myocytes were prepared as
previously described with some modifications (14). Briefly,
cardiac ventricles from one- or two-day-old Wistar rats
were minced and dissociated with 0.2% collagenase (Sigma
Type I). The dispersed cells were incubated in 100-mm
culture dishes (Falcon) for 60 min at 37°C, and the
nonattached cardiac myocytes were collected and seeded
into 100-mm culture dishes (8 3 106 cells per dish). The
myocytes were incubated in Dulbecco’s modified Eagle
medium (DMEM; Nissui Pharmaceutical, Tokyo, Japan)
supplemented with 10% fetal bovine serum (FBS; Bioserum
Lenexa, Kansas). Bromodeoxyuridine (BrdU, 100 mmol/
liter) was added during the first 48 h to prevent proliferation
of nonmyocytes.
At the end of the BrdU treatment, we routinely obtained
spontaneously beating myocyte-rich cultures (final cell den-
sity, 105 cells/cm2) with 90% to 95% myocytes, as assessed
by immunocytochemical test for myosin heavy chain (15).
The myocytes were then incubated for 36 to 48 h in
DMEM containing 0.5% FBS without BrdU, followed by a
final incubation in 10 ml fresh DMEM containing 0.5%
FBS. During this final incubation, cardiac myocytes were
treated with one of the following: 1) 1024 mol/ml or
1023 mol/liter sodium nitroprusside (SNP); 2) 1024 mol/
liter or 1023 mol/liter 8-bromo-cGMP; 3) 10 ng/ml IL-1b
in the presence or absence of 3 mmol/liter L-NMMA; 4) 10
ng/ml IL-1b in the presence or absence of 5 3 1024
mol/liter aminoguanidine; 5) 10 ng/ml IL-1b in the pres-
ence of 1027 mol/liter KT5823; or 6) 1023 mol/liter
8-bromo-cGMP in the presence of 1027 mol/liter KT5823.
Unless indicated otherwise, treatment was continued for
48 h at which time ATP and mitochondrial enzyme activity
were determined in the myocytes, and NOx (NO2
2/
NO3
2), glucose, and lactate concentrations were measured
in the culture media.
NOx assay. The NOx (nitrite and nitrate) concentrations
in the culture media were determined in an autoanalyzer
(ENO-10; Eicom, Kyoto, Japan). Samples were applied to
an analytical column combined with a copperized cadmium
reduction column to reduce NO3
2 to NO2
2, which was
then reacted with Griess reagent to produce a product
absorbing at 540 nm (16). Authentic NO2
2 and NO3
2
were used as reference standards.
Glucose and lactate analysis. Glucose concentration was
measured enzymatically using the Detaminer GL-E kit
(Kyowa Medics, Tokyo, Japan). Aliquots of culture media
were added to a phosphate-buffered reaction mix containing
2.4 IU/ml ascorbate oxidase, 0.7 mmol/liter sodium N-(2-
hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline (HSDA),
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2 IU/ml pyranose oxidase, 3.4 IU/ml peroxidase, and
0.4 mmol/liter 4-aminoantipyrine, at pH 6.5. Glucose
content was determined spectrophotometrically at 37°C by
measuring quinone absorbance at 585 nm.
Lactate content was measured enzymatically, using the
Detaminer LA kit (Kyowa Medics, Tokyo, Japan). Aliquots
of culture media were added to a phosphate-buffered reac-
tion mix containing 0.9 mmol/liter N-ethyl-N-(3-
methylphenyl)-N9-acethylethylendiamine (EMAE), 0.7
IU/ml lactate oxidase, 3.4 IU/ml peroxidase, and 0.4 mmol/
liter 4-aminoantipyrine, at pH 6.25. Lactate content was
determined spectrophotometrically at 37°C by measuring
quinone absorbance at 555 nm.
Measurement of ATP content. Cultured cardiac myocytes
(8 3 106 cells) were treated with 500 ml 0.6N ice-cold
perchloric acid and centrifuged at 3,000g for 5 min at 4°C.
The supernatants were neutralized with KOH to pH 5.0 to
7.0. After 10 min the extracts were centrifuged at 13,000g
for 5 min at 4°C to remove the KClO4, and the ATP in the
supernatants was measured by high-performance liquid
chromatography (HPLC: LC-9A liquid chromatograph,
Shimadzu, Kyoto, Japan) with a column of STR ODS-M
(Shimadzu) (17).
Mitochondrial isolation. Mitochondria were isolated ac-
cording to the method of Sordahl et al. (18), with some
modifications. Briefly, each culture dish (8 3 106 cells) was
washed with ice-cold phosphate buffered saline (PBS)
containing 15 mmol/liter Na2HPO4, 5 mmol/liter
NaH2PO4, 145 mmol/liter NaCl, at pH 7.3. The myocytes
were collected by scraping and were washed with ice-cold
buffer containing 25 mmol/liter K2HPO4, 25 mmol/liter
KH2PO4, and 1 mmol/liter EDTA, at pH 7.2. Pooled
myocytes (approximately 8 3 107 cells) were homogenized
in 1.6 ml of potassium-phosphate buffer containing
0.5 mmol/liter phenylmethanesulfonyl fluoride (PMSF)
with a Polytron PT 10-35 tissue processor (Kinematica
Instrument, Switzerland) three times at a setting of 7 for
10 s, and the homogenate was centrifuged at 27,000g for
10 min. The supernatant was discarded and the pellet was
suspended in 5 ml isolation medium consisting of 0.18
mol/liter KCl, 5 mmol/liter Tris-HCl, and 10 mmol/liter
EGTA, at pH 7.2. The suspension was centrifuged at
1,000g for 10 min, and the supernatant was collected and
centrifuged at 12,000g for 10 min. The mitochondrial pellet
was washed once and resuspended in 400 ml low-salt
medium consisting of 20 mmol/liter HEPES, 1.0 mmol/
liter MgCl2, and 2.0 mmol/liter EGTA, at pH 7.0. The
protein concentration in the mitochondrial suspension was
determined by the Lowry method (19).
Measurement of mitochondrial enzyme activity. Mito-
chondria were sonicated, and NADH-CoQ reductase ac-
tivity was assayed spectrophotometrically at 37°C by mea-
suring the initial rate of NADH oxidation at 340 nm in the
presence or absence of rotenone (15 mmol/liter), according
to the method of Hatefi and Rieske (20). Mitochondrial
succinate-CoQ reductase activity was assayed spectropho-
tometrically at 37°C by measuring the reduction of 2,6-
dichloroindophenol sodium (DCIP) at 600 nm, according
to the method of Ziegler and Rieske (21). Mitochondrial
ATPase activity was measured spectrophotometrically by
coupling the reaction to a pyruvate kinase and lactate
dehydrogenase system, according to the method of Lowe
(22). Mitochondrial ATPase activity was determined at
37°C by monitoring the decline of NADH oxidation at
340 nm in the presence or absence of oligomycin
(10 ng/ml).
Electrophysiology. A whole-cell voltage-clamp method
was applied to the isolated neonatal cells to measure calcium
current (ICa) (23). Current clamp mode was used in the
whole-cell configuration when membrane potential was
recorded. An Axopatch 200A amplifier (Axon Instrument,
Foster City, California) was used for this purpose. All data
were digitized by DigiData 1200 A/D converter (Axon
Instrument). Data acquisition and commands were con-
trolled with pClamp software (version 6.0; Axon Instru-
ment). Electrodes were prepared from glass capillaries with
filament (outer diameter 1.2 mm; inner diameter 1.0 mm,
Narishige, Tokyo, Japan), and filled with a solution con-
taining 1) current clamp mode: 120 mmol/liter KCl,
10 mmol/liter NaCl, 1 mmol/liter MgCl2, and 20 mmol/
liter HEPES, pH 7.3, adjusted with KOH; 2) voltage clamp
mode: 125 mmol/liter L-aspartic acid, 25 mmol/liter
tetraethyl-ammonium chloride, 5 mmol/liter Na2ATP,
1 mmol/liter MgCl2, 1 mmol/liter EGTA, and 5 mmol/
liter HEPES, pH 7.3, adjusted with CsOH, whose final
concentration was 160 mmol/liter.
Membrane potential was recorded continuously in cur-
rent clamp mode while cells were superfused with a modi-
fied Tyrode solution whose composition was as follows:
135 mmol/liter NaCl, 5.4 mmol/liter KCl, 1.8 mmol/liter
CaCl2, 1 mmol/liter MgCl2, 0.33 mmol/liter NaH2PO4,
10 mmol/liter HEPES, 10 mmol/liter glucose, pH 7.4,
adjusted with NaOH. The ICa was recorded every 10 s in
voltage clamp mode. The KCl in superfusing solution was
replaced with 20 mmol/liter CsCl2 in this mode. Membrane
voltage was held at 280 mV for 9.5 s, stepped up to
240 mV for 0.25 s to inactivate sodium current, and then
jumped to 0 mV for 0.25 s to evoke ICa. Peak ICa was
measured relative to the zero-current level.
Contractility. Nomarski differential interference-contrast
microscopy with enclosed heated chamber (Nikon
DIAPHOT-TMD300) was used for visualization of cardiac
myocytes. A series of images of cardiac myocytes during a
contraction was recorded on the charge-coupled device
(CCD; Nikon Instech/SONY LVR-3000AN-NS). Cell
length was determined directly from the images using an
edge-detection system.
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Statistical analysis. All experiments were repeated at least
six times. The data in Figures 1 and 2 were analyzed by
two-way analysis of variance (ANOVA), and the data at
each time point were analyzed by one-way ANOVA and
Bonferroni’s multiple comparison. The data in Figures 3–8
were also analyzed by one-way ANOVA and Bonferroni’s
multiple comparison. Data are expressed as mean 6 SE, and
a p-value of less than 0.05 was considered to be statistically
significant.
RESULTS
Cell death in cultured cardiac myocytes. Following our
previously described histochemical methods (24) we em-
ployed combined staining with Hoechst 33258, desmin, and
in-situ end-labeling (ISEL) of fragmented DNA to monitor
apoptosis of the isolated cardiomyocytes (24). We did not
observe apoptosis in cells grown in 0.5% FBS for up to 48 h
with or without IL-1b treatment (data not shown). We also
did not detect a significant increase in creatine kinase
activity in the media, or trypan blue uptake by the treated
cells, thus ruling out an increase in necrotic cell death (data
not shown).
Induction of NOx production by IL-1b. Because NO is
rapidly oxidized to more stable products such as nitrite and
nitrate, NO production in the cultured myocytes was
evaluated by measuring NOx in the culture media. IL-1b (0
to 100 ng/ml) increased NOx production in a dose-
dependent fashion, reaching a near-maximum of 225 6
20 nmol/mg protein at 10 ng IL-1b /ml after 24 h (data not
shown). We therefore used this concentration of IL-1b for
the subsequent experiments.
The time-dependent kinetics of NOx production are
shown in Figure 1. Treatment of myocytes with 10 ng/ml
IL-1b for 48 h caused a marked linear accumulation of NOx
in the culture media to levels approximately 11-fold greater
than control. The IL-1b–induced NOx production was
completely inhibited by co-incubation with 3 mmol/liter
L-NMMA, an inhibitor of NO synthesis. Prolonged incu-
bation with SNP, an exogenous NO donor, also increased
NOx concentration in a dose- and time-dependent manner,
with 1024 mol/liter and 1023 mol/liter SNP increasing
NOx levels by 5- and 14-fold over control, respectively, after
48 h.
Lactate accumulation. Interleukin-1b increased lactate
concentration in the culture media in a time-dependent
manner (Fig. 2). Treatment with IL-1b for 48 h resulted in
a marked accumulation of lactate in the culture media to
levels approximately four-fold greater than control. Lactate
production was significantly inhibited by 3 mmol/liter
L-NMMA. Also, SNP significantly increased lactate pro-
duction in a dose-dependent manner. With both IL-1b and
SNP, lactate production declined after 24 h. In contrast,
treatment with 8-bromo-cGMP, an exogenous cGMP do-
nor, did not significantly increase lactate accumulation.
Glucose consumption. The glucose consumption rate was
calculated from the difference between the concentration of
glucose in the culture media before, and 24 h after,
incubation (Fig. 3). Treatment of myocytes with IL-1b
Figure 1. Time course of NO2
2/NO3
2 (NOx) production. Car-
diac myocytes were incubated with either (a) 1024 mol/liter or
1023 mol/liter sodium nitroprusside (SNP), or (b) 10 ng/ml IL-1b
(IL) in the presence or absence of 3 mmol/liter NG-monomethyl-
L-arginine (L-NMMA) for the indicated time, and NOx produc-
tion in the culture media was measured as described in Methods.
Control preparations contained no additives. The interaction
between five groups and time course was significant (p , 0.0001).
§p , 0.0001 vs. control (n 5 6).
Figure 2. Time course of lactate production. Cardiac myocytes
were incubated with (a) 1024 mol/liter or 1023 mol/liter sodium
nitroprusside (SNP), (b) 1024 mol/liter or 1023 mol/liter 8-bromo
cGMP, or (c) 10 ng/ml IL-1b (IL) in the presence or absence of
3 mmol/liter NG-monomethyl-L-arginine (L-NMMA) for the
indicated time, and lactate production was measured in the media
as described in Methods. Control preparations contained no
additives. The interaction between seven groups and time course
was significant (p , 0.0001). §p , 0.0001 vs. control (n 5 6).
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increased glucose consumption by almost two-fold over
control. This increase in glucose consumption was com-
pletely abolished by L-NMMA. The SNP also significantly
increased glucose consumption. In contrast, 8-bromo-
cGMP did not affect the glucose consumption rate in the
cardiac myocytes. Glucose consumption in myocytes treated
with either IL-1b or SNP declined significantly by 48 h
(data not shown).
ATP content. The ATP content in the control cultured
myocytes did not change for up to 48 h of incubation.
However, ATP concentration decreased to 78% of control
in myocytes treated with IL-1b after 48 h (Fig. 4). This
decline in ATP content was completely blocked by
3 mmol/liter L-NMMA. Also, SNP decreased ATP con-
tent significantly in a dose-dependent manner. In contrast,
8-bromo-cGMP did not alter ATP content. KCN
(1024 mol/liter or 1023 mol/liter), a mitochondrial inhibi-
tor, significantly decreased ATP content in a dose-
dependent manner in cultured myocytes. However, the
decline in ATP content induced by KCN alone was signif-
icantly smaller than that caused by SNP. Moreover, when
added to myocytes treated with IL-1b or SNP, KCN
significantly exacerbated the inhibition of ATP production,
further lowering ATP content by an additional 10% after
48 h (data not shown).
Mitochondrial enzyme activities. Treatment of cultured
myocytes with IL-1b for 24 h significantly lowered the
activities of mitochondrial NADH-CoQ reductase and
succinate-CoQ reductase to 76% and 78% of control,
respectively (Fig. 5). Continuing IL-1b treatment for 48 h
further exacerbated this inactivation (data not shown). The
L-NMMA completely abolished the IL-1b–induced sup-
pression of these activities. Moreover, SNP also significantly
decreased the activities of these enzyme in a dose-dependent
manner. The activity of oligomycin-sensitive ATPase did
not change with IL-1b or SNP. The activities of these
enzymes were not affected by 8-bromo-cGMP.
Electrophysiological effects. Maximum diastolic potential
was 254 6 2.8 mV in control cells (n 5 16), 232 6
3.4 mV in IL-1b–treated cells (n 5 19, p , 0.001 vs.
control), and 225 6 3.0 mV in SNP 1023 mol/liter-treated
cells (n 5 7, p , 0.001 vs. control) (Fig. 6). Action potential
duration fluctuated with the maximum diastolic potential,
and neither IL-1b nor SNP significantly affected this
duration. The ICa was evoked at a membrane potential of
0 mV. Peak ICa was 584 6 89 pA in control cells but was
significantly lowered with IL-1b, SNP, or 8-bromo-cGMP
(Fig. 7). The IL-1b–induced decline in peak ICa was
significantly blocked by aminoguanidine or L-NMMA.
KT5823, an inhibitor of cGMP-dependent protein kinase,
did not significantly affect the IL-1b–induced reduction in
ICa, although it almost completely restored the 8-bromo-
cGMP–induced loss of ICa.
Contractility. Treatment of myocytes with either SNP or
IL-1b significantly decreased contractility after 48 h (Fig.
8). This IL-1b–induced decrease in contractility was com-
pletely blocked by aminoguanidine or L-NMMA. The
Figure 3. Glucose consumption rate in cardiac myocytes. Myo-
cytes were incubated with (a) 1024 mol/liter or 1023 mol/liter
sodium nitroprusside (SNP), (b) 1024 mol/liter or 1023 mol/liter
8-bromo cGMP, or (c) 10 ng/ml IL-1b (IL) in the presence or
absence of 3 mmol/liter NG-monomethyl-L-arginine (L-NMMA)
for 24 h, and glucose consumption rate was measured as described
in Methods. Control preparations received no additives. §p ,
0.0001 vs. control (n 5 6).
Figure 4. ATP content in cardiac myocytes. Myocytes were
incubated with (a) 1024 mol/liter or 1023 mol/liter sodium
nitroprusside (SNP), (b) 1024 mol/liter or 1023 mol/liter 8-bromo
cGMP, or (c) 10 ng/ml interleukin (IL)-1b in the presence or
absence of 3 mmol/liter NG-monomethyl-L-arginine (L-NMMA)
for 48 h, and ATP content was measured as described in Methods.
Control preparations received no additives. †p , 0.01; ‡p , 0.001;
§p , 0.0001 vs. control (n 5 6).
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addition of KT5823 did not restore contractile function in
IL-1b–treated myocytes.
DISCUSSION
This study shows for the first time that cytokine-induced NO
production in neonatal cardiac myocytes causes the attenuation
of cellular energy production as a result of the direct inhibition
of mitochondrial enzymes. This inhibition was associated with
the disruption of the electrophysiological properties of these
cells, and an attendant contractile dysfunction. We show that
treatment of myocytes with the proinflammatory cytokine
IL-1b causes the inhibition of mitochondrial respiration, an
increase in anaerobic glycolysis and lactate production, and a
resultant decline in ATP. Therefore, the principal significance
of our data is that the data provide a direct molecular link
between the overproduction of NO and the physiological
manifestations of the resultant injury in inflamed myocardium.
Figure 5. Mitochondrial enzyme activity in cardiac myocytes. Myocytes were incubated in the presence of 10 ng/ml IL-1b (IL), with or
without 3 mmol/liter NG-monomethyl-L-arginine (L-NMMA), and 1024 mol/liter or 1023 mol/liter sodium nitroprusside (SNP). The
activity of the indicated mitochondrial enzymes was assayed as described in Methods. Control preparations received no additives. All
activities are in units of mmol/min/mg protein. †p , 0.01; §p , 0.0001 vs. control (n 5 6).
Figure 6. Electrophysiological effects in cardiac myocytes. Representative traces show membrane potential and calcium current (ICa) in
myocytes treated with 10 ng/ml IL-1b (IL) or 1023 mol/liter sodium nitroprusside (SNP) as described in Methods.
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Three lines of evidence confirm that NO was indeed the
effector molecule for these changes. First, SNP, a NO
donor, mimicked these injurious effects. The fact that
cyanide alone did not cause similar effects rules out the
possibility that the effect of SNP was caused by the release
of CN2. Second, L-NMMA, a competitive antagonist of
NOS, completely blocked the detrimental effects of IL-1b.
Third, aminoguanidine, a selective iNOS inhibitor, blocked
the NO-induced electrophysiological effects. Our data,
therefore, strongly suggest that the overproduction of NO
by iNOS can cause direct injury to the mitochondrial
respiratory machinery, inhibit energy production, and cause
contractile dysfunction. The fact that the cGMP analogue,
8-bromo-cGMP, did not have any deleterious effects on
mitochondrial activity, ATP content, glucose consumption,
or lactate production indicates that the effect of NO was
direct and was not mediated through the activation of
soluble guanylate cyclase.
NO and mitochondrial respiration. It is presently well-
established that IL-1b can induce the expression of iNOS
in cardiac myocytes (13), resulting in a burst of NO
production capable of causing negative inotropic, or out-
right cytotoxic, effects (3–5). Recent studies have also shown
that cytokine-induced NO production can inhibit mito-
chondrial activity in isolated cardiac myocytes (11,12).
Moreover, other studies, measuring tissue O2 consumption,
have shown that NO release from vascular endothelial cells
appears to play an important physiological role in the
regulation of mitochondrial respiration in skeletal muscle
(25). However, our study is the first to establish that
NO-induced mitochondrial dysfunction causes myocardial
energy depletion in cardiomyocytes, and we demonstrate a
link between this energy reduction and contractile dysfunc-
tion.
In addition, it is noteworthy that most of the previous
studies in this field incubated the myocytes in serum-
deprived medium for prolonged periods of time. These
culture conditions may have resulted in significant apoptosis
(26), thereby confounding the cytokine effects. In contrast,
the present study was carried out in medium containing
0.5% FBS, which did not cause apoptosis in our hands
either with or without IL-1b treatment (data not shown).
The specific targets of NO in the mitochondria remain to
be fully elucidated. Recently, NO was shown to cause the
inhibition of mitochondrial respiration in macrophages
(27), as well as in cultured smooth muscle cells, by inhibit-
ing complex I and II activity (9). The inhibition of cyto-
chrome oxidase was also demonstrated in isolated cardiac
myocytes exposed to a combination of IL-1b and INF-g
(12). Our present study sheds additional light on this issue
by demonstrating that both endogenous (IL-1b induced)
and exogenous (SNP induced) NO inhibits the mitochon-
drial enzymes NADH-CoQ reductase and succinate-CoQ
reductase—metalloproteins containing iron-sulfur clusters
known to be highly sensitive to direct oxidative modification
by the free radical NO (28). Previous studies have demon-
strated that NO can react with the metal clusters in these
enzymes to form injurious nitrosyl complexes (29,30). Our
data suggest that the injurious effects of NO are probably
oxidative in nature. It is not clear at this time why the
Figure 7. Peak calcium current in cardiac myocytes. The cells were
incubated with 10 ng/ml IL-1b (IL) in the presence or absence of
1027 mol/liter KT5823, 5 3 1024 mol/liter aminoguanidine
(AG), and 3 mmol/liter NG-monomethyl-L-arginine (L-
NMMA), 1023 mol/liter 8-bromo cGMP in the presence or
absence of 1027 mol/liter KT5823, or 1023 mol/liter sodium
nitroprusside (SNP) for 48 h, and calcium current (ICa) was
measured as described in Methods. §p , 0.0001 vs. control; #p ,
0.01 vs. 8-bromo-cGMP (n 5 13).
Figure 8. Myocyte contractility. The cells were incubated with
10 ng/ml IL-1b (IL) in the presence or absence of 1027 mol/liter
KT5823, 5 3 1024 mol/liter aminoguanidine (AG), and 3
mmol/liter NG-monomethyl-L-arginine (L-NMMA), or 1023
mol/liter sodium nitroprusside (SNP) for 48 h, and cell shortening
was measured as described in Methods. §p , 0.0001 vs. control
(n 5 10).
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oligomycin-sensitive ATPase was not inhibited by our
experimental conditions.
NO and energy metabolism. Inhibition of the respiratory
enzymes by NO in our study dictates that the rate of
anaerobic glycolysis increases in the myocytes to compensate
for the reduced energy supply. Such increased activity of the
glycolytic pathway would rapidly increase glucose consump-
tion and lactate production. The present study did, in fact,
document these characteristic changes in both the IL-1b–
treated and SNP-treated myocytes. This effect was totally
inhibited by L-NMMA, but was not mimicked by the
addition of exogenous 8-bromo-cGMP, confirming that the
inhibitory action of NO was not mediated through intra-
cellular signaling by NO-inducible soluble guanylate cyclase
(31).
In view of its lower energy-yielding potential, anaerobic
glycolysis would not be expected to maintain normal ATP
content in the actively beating myocytes. This, and the
increased acidotic conditions known to accompany anaero-
bic glycolysis and lactate production, would presumably
cause the ultimate inhibition of myocyte contractility (32–
34). We did, in fact, observe ATP depletion, electrophysi-
ological alterations, and contractile dysfunction in IL-1b–
treated myocytes. The decline in ATP content, which
reached approximately 25% after 48 h of IL-1b treatment,
was inhibited by L-NMMA. Exogenous SNP also pro-
duced a substantial decrease in ATP content, providing
support for the direct involvement of NO. Moreover, the
addition of the respiratory inhibitor cyanide to the IL-1b–
treated cells significantly exacerbated ATP depletion, con-
firming that, in our model, ATP depletion was dependent
on the severity of inhibition of glycolysis and mitochondrial
respiration.
Energy depletion and cell dysfunction. Reduced energy
production in mitochondria in the presence of IL-1b should
result in impairment of cell function. Our data show
elevated maximum diastolic potential, reduced peak ICa, and
reduced contractility in IL-1b- or SNP-treated myocytes.
This loss in contractility is presumably attributable to the
inactivation of the calcium current and lower calcium entry
(35,36). KT5823, a selective inhibitor of cGMP-dependent
protein kinase (37), did not significantly restore the IL-1b–
induced reduction of ICa, but it did reverse the effects of
8-bromo-cGMP, confirming that the NO-induced ATP
depletion directly alters intrinsic cellular activity, indepen-
dently of cGMP-associated signaling pathways. Thus, our
data strongly suggest that direct inactivation of the mito-
chondrial energy-producing apparatus by NO, and the
resultant disruption of calcium regulation, are both the
likely cause of the cessation of contractile activity.
However, at this time we cannot exclude the possibility
that direct inactivation of calcium-regulating membrane
proteins may also contribute to this effect. Our studies
demonstrated a decline in ATP of only 25%, which may not
be sufficient to account for the cessation of contractility. In
fact, the possibility of modulation of the calcium-regulatory
apparatus by NO in a similar model was raised recently by
Bick et al. (38), who showed that treatment of myocytes
with a number of cytokines, including IL-1b, for 2 or 18 h
resulted in increased calcium transients and contractility,
suggesting that NO may directly affect sarcolemmal func-
tion. We are unable to explain this apparent discrepancy
between our two conflicting sets of data. However, in their
conclusions, Bick et al. emphasize the time-dependent
nature of their observed effects. The apparent conflict may
therefore reflect the much longer incubation time that we
employed.
Conclusions. In summary, therefore, the present study
shows that NO production in cardiac myocytes in response
to the inflammatory mediator IL-1b causes the inactivation
of selected oxidant-sensitive mitochondrial enzymes, result-
ing in the inhibition of mitochondrial respiration, energy
depletion, electrophysiological dysfunction, and strong in-
hibition of contractility. Because we did not detect a
significant increase in apoptosis or necrosis, our observations
are unlikely to be attributable to nonspecific toxicity by NO.
Our data suggest that the inhibition of respiration is not
caused by means of cGMP, but is attributable in large
measure to the direct oxidative modification by NO of
mitochondrial enzymes.
We cannot discount, at this time, the possibility that the
production of O2
2 and/or H2O2 by iNOS (39,40), or the
production of peroxynitrite from NO and O2
2 (41), may
have contributed to this oxidative stress. Nor can we exclude
the possibility that this injury is compounded by multiple
other known effects of NO such as the auto-ADP-
ribosylation of glycolytic enzymes (42), inhibition of ribo-
nucleotide reductase (43), activation of poly (ADP-ribose)
synthetase (44), inhibition of the citric acid enzyme aconi-
tase (45), or others. However, the present study provides
strong evidence for the production of excessive and injurious
amounts of NO during cardiac inflammatory reactions that
can have significant direct detrimental effects on cardiac
respiration and contractility. Knowledge that these detri-
mental effects of NO may be caused largely by direct
oxidation of mitochondrial enzymes may prove useful in
designing protective therapies for inflammation-induced
myocardial injury.
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